QED

QBGJ398-301

NCT03773302

JCP068

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions / Translocations

Status:

Recruiting

26459-200.png

III

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Early Cancer

Disease Stage

Target.png

Biomarker(s)

FGFR2

Investigational

Product

Infigratinib (BGJ398)

Selective FGFR1-3 inhibitor (p.o.)

Treatment Arms

o  Experimental: Infigratinib (BGJ398) 125 mg

o  Active Comparator: Gemcitabine + Cisplatin